))
UK Bans Puberty Blockers, EMA Rejects Alzheimer's Drug, New Blood Test Shows Promise
Manage episode 431307379 series 3078043
Inhalt bereitgestellt von Dr Ferghal Armstrong - FAChAM. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Dr Ferghal Armstrong - FAChAM oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
In today's episode, we cover some major stories in medical news:
First up, the UK High Court has upheld a ban on puberty blockers for youth with gender dysphoria, citing a lack of evidence for their safety and effectiveness. While trans advocacy groups plan to appeal, the ruling limits use to clinical trials for now.
Next, the European Medicines Agency has rejected a license for a promising new Alzheimer's drug called lacanumab over safety concerns, despite the drug showing ability to slow cognitive decline by 25% in trials. The setback is disappointing for many hoping for a treatment.
Finally, an exciting development on the diagnostic front - a new blood test called AP's-2 has demonstrated over 90% accuracy in diagnosing early-stage Alzheimer's, outperforming primary care doctors. The test could revolutionize early detection if approved.
119 Episoden
Teilen
